Concert Pharmaceuticals (CNCE) Upgraded to Hold at Zacks Investment Research

Concert Pharmaceuticals (NASDAQ:CNCE) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday.

According to Zacks, “Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. “

A number of other analysts also recently commented on the stock. BidaskClub downgraded shares of Concert Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, December 22nd. UBS Group set a $34.00 target price on shares of Concert Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 19th. Mizuho cut shares of Concert Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $23.00 target price for the company. in a research report on Friday, January 12th. Stifel Nicolaus restated a “buy” rating and set a $27.00 target price on shares of Concert Pharmaceuticals in a research report on Friday, January 12th. Finally, TheStreet upgraded shares of Concert Pharmaceuticals from a “d” rating to a “c+” rating in a research report on Wednesday, November 29th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $24.33.

Concert Pharmaceuticals (CNCE) traded down $0.13 during mid-day trading on Monday, reaching $19.96. 263,848 shares of the company were exchanged, compared to its average volume of 541,533. The stock has a market capitalization of $457.50, a P/E ratio of 5.37 and a beta of 1.23. Concert Pharmaceuticals has a 52-week low of $9.01 and a 52-week high of $30.71.

Concert Pharmaceuticals (NASDAQ:CNCE) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.16). The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. Concert Pharmaceuticals had a negative return on equity of 51.48% and a net margin of 62.31%. analysts predict that Concert Pharmaceuticals will post 4.1 EPS for the current year.

In other Concert Pharmaceuticals news, Director Richard Aldrich sold 31,236 shares of Concert Pharmaceuticals stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $19.14, for a total transaction of $597,857.04. Following the completion of the transaction, the director now owns 286,975 shares in the company, valued at $5,492,701.50. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Value Fund L. P. Biotechnology sold 1,282,856 shares of Concert Pharmaceuticals stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $26.65, for a total transaction of $34,188,112.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,433,248 shares of company stock valued at $37,226,329. 10.10% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. raised its position in shares of Concert Pharmaceuticals by 57.2% in the fourth quarter. BlackRock Inc. now owns 1,786,223 shares of the biotechnology company’s stock valued at $46,210,000 after buying an additional 649,808 shares during the last quarter. Ingalls & Snyder LLC raised its position in shares of Concert Pharmaceuticals by 8.7% in the fourth quarter. Ingalls & Snyder LLC now owns 1,314,562 shares of the biotechnology company’s stock valued at $34,008,000 after buying an additional 105,500 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Concert Pharmaceuticals by 11.0% in the second quarter. Vanguard Group Inc. now owns 756,513 shares of the biotechnology company’s stock valued at $10,553,000 after buying an additional 74,801 shares during the last quarter. Lyon Street Capital LLC raised its position in shares of Concert Pharmaceuticals by 6.5% in the third quarter. Lyon Street Capital LLC now owns 463,064 shares of the biotechnology company’s stock valued at $6,830,000 after buying an additional 28,312 shares during the last quarter. Finally, Alyeska Investment Group L.P. raised its position in shares of Concert Pharmaceuticals by 1.8% in the third quarter. Alyeska Investment Group L.P. now owns 368,243 shares of the biotechnology company’s stock valued at $5,432,000 after buying an additional 6,576 shares during the last quarter. 67.44% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Concert Pharmaceuticals (CNCE) Upgraded to Hold at Zacks Investment Research” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/12/concert-pharmaceuticals-cnce-upgraded-to-hold-at-zacks-investment-research.html.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Get a free copy of the Zacks research report on Concert Pharmaceuticals (CNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply